Judge Axes 1 Tyvaso Patent, Finds Another Was Infringed

By Jasmin Jackson (September 1, 2022, 9:16 PM EDT) -- A Delaware federal judge has invalidated one of United Therapeutics' drug patents for hypertension drug Tyvaso for lack of enablement, but also held that rival Liquidia's planned generic infringes a different Tyvaso patent despite an administrative tribunal's earlier decision to ax it....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!